The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...

Enrollment of pivotal cohort expected to begin in Q1 2026; ATSN-201 BLA submission on track for early 2028DURHAM, N.C., Jan. 08, 2026 (GLOBE ...

Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...

DUBLIN, Jan. 7, 2026 /PRNewswire/ -- LUMA Vision Ltd., a leader in cardiac 4D navigation and imaging, today announced the ...

Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...

Abstract: Due to the substantial gap between vision and language modalities, along with the mismatch problem between fixed language descriptions and dynamic visual information, existing ...

For the first time anywhere in the world, Lumin Fitness, a leader in responsive artificial intelligence training environments, announced a partnership with The University of Texas Health East Texas ...

Successful change leaders strategically track and navigate complexity with intelligence, intuition, curiosity, courage, and agility. They embody patience, focused attention, and deep connection to ...

No significant difference in visual improvement was observed between patients with giant cell arteritis who received intravenous glucocorticoids vs oral therapy. Patients with giant cell arteritis ...

Please provide your email address to receive an email when new articles are posted on . Clinical signs and symptoms were improved after 12 weeks of therapy compared with 6 weeks of observation.

Summary: Concussions can leave lasting effects on vision, with nearly half of young patients experiencing disorders that disrupt daily life and delay return to normal activities. A new study shows ...

A new approach to gene therapy for retinitis pigmentosa may help patients with advanced disease regain vision regardless of which genetic mutation is causing the condition. An optogenetic therapy ...